Key result
Low-dose metronomic cyclophosphamide showed absent or moderate hematologic and intestinal toxicity compared to maximum tolerated dose regimens, though it caused sustained lymphopenia.
Why the study?
Does low-dose metronomic cyclophosphamide reduce toxicity on sensitive tissues compared to maximum tolerated dose cyclophosphamide?
Population
Experimental models (specifics not detailed in abstract)
Comparison
Low-dose metronomic (LDM) cyclophosphamide vs Maximum tolerated dose (MTD) cyclophosphamide
Design
Preclinical
Authors
Loading...
May reduce toxicity versus MTD cyclophosphamide in animal models; leaves open translation to human antiangiogenic regimens.
Does low-dose metronomic cyclophosphamide reduce toxicity on sensitive tissues compared to maximum tolerated dose cyclophosphamide?
Low-dose metronomic cyclophosphamide offers clear safety advantages over conventional maximum tolerated dose chemotherapy, making it potentially ideal for long-term combination therapy with antiangiogenic drugs.
Emmenegger et al. (2004) studied Metastatic malignancy. Low-dose metronomic cyclophosphamide vs. Maximum tolerated dose cyclophosphamide was evaluated on Toxicity on bone marrow, gut mucosa, wound healing, and organ toxicity. Low-dose metronomic cyclophosphamide showed absent or moderate hematologic and intestinal toxicity compared to maximum tolerated dose regimens, though it caused sustained lymphopenia.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: